Though the Ready, Set, Growth! Biotech Benchmark Report 2024 documented that women’s health is still critically underfunded, it is trending in a positive direction like the rest of the biotech market. After the dark days of 2022 and 2023, 2024 feels like a fresh start for the biotech and healthcare industry — and it shows no signs of slowing down.
Despite some unnerving economic indicators in the macro economy, including waning consumer confidence and stubborn inflation, biotech seems to be on an upswing. There is no telling how long it will last, but innovations, including cell and gene therapy, machine learning and gene editing, promise to continue driving innovation for years into the future. Even if future policy decisions hamper the industry in the short term, stakeholders are confident that the market’s resilient nature will shine through and continue its lifesaving work.